Advertise on podcast: This Medical Life

New guidelines are here. The Prostate Cancer Foundation of Australia and the Australian Government Department of Health, Disability and Ageing have released the 2026 Guidelines for the Early Detection of Prostate Cancer. One in seven Australian men will be diagnosed with prostate cancer. The aim is to find early prostate cancer in the men most at risk, while sparing low-risk men tests they do not need. The story starts in forensic science. In the 1960s, crime labs needed a better way to detect semen than finding sperm, which break down within minutes to an hour. Dr Travis Brown explains how the Japanese forensic scientist Mitsuhara identified a protein he called gamma-seminoprotein. Teams at Cornell and the University of California found the same protein under other names. Today we call it PSA. By the 1970s, researchers saw it was raised in advanced prostate cancer, and its long, debated path as a screening test began. The last guidelines came out in 2016. Since then, two things have shifted the balance of risk and benefit: access to multiparametric MRI, and the move from transrectal to transperineal biopsy. In this episode, Ken walks through the key changes: Free-to-total PSA ratio is no longer needed. MRI is better at sorting risk. About 80% of men with a confirmed PSA above 3 already have a free-to-total ratio below 25%. Ages 45 to 49 (higher risk): refer when PSA is above 1 ng/mL. This group includes men with a brother with prostate cancer, a father diagnosed at 65 or younger, or a BRCA mutation. Ages 50 to 69: the threshold stays at 3 ng/mL, or 2 ng/mL for higher-risk men. Ages 70 and over: for men likely to live more than seven years, the threshold is 5.5 ng/mL. Men below 5.5 can reasonably stop testing. Repeat the test in one to three months. About 30% of men with a PSA above 3 will test well below 3 on repeat, often due to BPH-related variation. GPs should now start the conversation. The 2016 guidelines had GPs respond when a man raised it. The new guidelines, endorsed by the RACGP, ask GPs to raise PSA testing with men aged 50 to 69. Not for prostate cancer screening. In the evidence, rectal exams by non-specialists added as many false positives as false negatives. Ken notes that urologists still gain useful information from it, and a rectal exam remains relevant when you are looking for rectal cancer. Men with a first-degree relative with prostate cancer, men with BRCA mutations, and men of African ancestry. The guidelines also name Aboriginal and Torres Strait Islander men as a priority population because of poorer access to care. Ken adds that men in regional Victoria have worse prostate cancer outcomes than men in the city. This is the story of the 2026 Early Detection of Prostate Cancer. Useful Link: 2026 Guidelines for the Early Detection of Prostate Cancer in Australia Our Special Guest: Professor Ken Sikaris is a chemical pathologist and head of clinical integration at Dorevitch Pathology. He is a NATA laboratory assessor, a founding fellow of the RCPA Faculty of Science and a principal examiner in pathology informatics. Ken was one of the first people to measure PSA in Australia, bringing in some of the first test kits around 1989. He helped write the new guidelines. Listen: This Medical Life podcast is available on all podcasting services, Apple Podcasts, YouTube, and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page. See omnystudio.com/listener for privacy information.

In 1880, a French physician described a patient having up to 200 sleep attacks a day, some triggered by nothing more than a good hand of cards or the sight of his own wine barrels. That case, and an earlier 1877 description from German psychiatrist Carl Westphal, gave the condition its name and its first clinical picture. Dr Travis Brown reads from both original case reports before turning to two guests for where narcolepsy stands today. Di Spillaine, an Australian narcolepsy advocate and lived experience educator, describes going almost 40 years undiagnosed, mistaking her symptoms (childhood hallucinations, cataplexy triggered by laughter, sleep paralysis) for ordinary tiredness until a multiple sleep latency test finally confirmed narcolepsy. Professor Robert Adams, a respiratory and sleep physician at Flinders Medical Centre and medical director of the Adelaide Institute for Sleep Health, explains the underlying orexin deficiency behind narcolepsy type 1, how it differs from everyday tiredness and other sleep disorders, and the diagnostic pathway, including the Epworth Sleepiness Scale and multiple sleep latency testing. What to listen for: the questions Professor Adams suggests a GP ask beyond “are you tired”, and why narcolepsy sits, in his words, at the end of the queue of likely causes but should still be considered in young patients with long-standing, profound sleepiness. This is the story of narcolepsy. Useful Link: Epworth sleepiness scale: https://www.cdc.gov/niosh/work-hour-training-for-nurses/02/epworth.pdf Our Special Guests: Di Spillaine is an Australian narcolepsy advocate, lived experience educator and creator of the podcast Waking Up Tired: Narcolepsy Symptoms Explained Professor Robert Adams is a respiratory and sleep physician at Flinders Medical Centre and medical director of the Adelaide Institute for Sleep Health at Flinders University Listen: This Medical Life podcast is available on all podcasting services, Apple Podcasts, YouTube, and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page. See omnystudio.com/listener for privacy information.

Sexual harassment in medicine is almost universally perpetrated by men, and in over half of doctor-on-doctor cases, it happens in the workplace itself, not at a conference or a staff event. That is one of the findings from a decade of research by Dr Louise Stone, who began this work in 2014 after a young intern disclosed a sexual assault to her in consultation. Dr Travis Brown speaks with Dr Louise Stone, a professor of general practice with expertise in doctors’ health, sexual safety and professionalism, about what her research uncovered. Dr Stone identifies two distinct groups of perpetrators: persistent predators who choose careers with access to power, and a smaller group of senior doctors, often isolated by decades of on-call work, who form inappropriate attachments without the same pattern of repeat behaviour. She explains why junior doctors on rotating three-month terms are especially vulnerable, why specialties such as surgery, psychiatry and pathology carry disproportionate risk, and why zero tolerance policies tend to drive the problem underground rather than reduce it. She also sets out what she has found does help: peer intervention from someone at the same level of seniority as the person behaving badly, and giving survivors clarity on what they actually want from a reporting process, whether that is justice, protection of others, or simply healing. What to listen for: The early warning signs Dr Stone flags for junior doctors and medical students, and why a colleague’s discomfort is worth naming rather than dismissing. This is the story about sexual harassment in medicine. Our Special Guest: Dr Louise Stone is a professor of general practice, previous lead medical educator for GP training in Australia, and author of Sexual Harassment Between Doctors: Healing Medical Cultures Around the World, available from her website: https://www.drlouisestone.com Listen: This Medical Life podcast is available on all podcasting services, Apple Podcasts, YouTube, and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page. See omnystudio.com/listener for privacy information.

One doctor’s case from 1901 changed how we understand memory loss. Auguste Deter was 51 when her husband Carl brought her to see Dr Alois Alzheimer in Frankfurt, worried by memory lapses that had turned into paranoia and confusion. When Auguste died five years later, Alzheimer examined her brain and found two things under the microscope: amyloid plaques between nerve cells and neurofibrillary tangles within them. His 1906 presentation to a room of psychiatrists drew no questions at all. It was not until 1910, when Emil Kraepelin included the case in his Handbook of Psychiatry, that the term Alzheimer’s disease appeared in print for the first time. Dr Liam Mulcahy, physician trainee and author of Beyond the White Coat, traces that discovery in detail, then Dr Travis Brown turns to two guests for where the disease stands in 2026. Dr Daniel Clarke, consultant neurologist at Sir Charles Gairdner Hospital and director of clinical trials at Alzheimer’s Research Australia, covers how Alzheimer’s actually presents (often nothing like the stereotype), why history remains the most important diagnostic tool, and why non-pharmacological measures such as exercise and vascular risk control come before medication. He also explains why family history is often overrated, and why he does not recommend routine APOE4 gene testing. Dr Gemma Daley, consultant chemical pathologist at Sullivan Nicolaides Pathology, explains what the new p-tau181 and p-tau217 blood tests can and cannot tell a GP, who should and should not be referred for them, and why they are adjunctive tests rather than standalone diagnostic tools. What to listen for: the presenting features that separate Alzheimer’s from ordinary age-related forgetfulness, and what a negative or positive p-tau result actually means for a patient in front of you. This is the story of Alzheimer’s disease. Useful links: Dementia Australia: https://www.dementia.org.au/ Alzheimer’s Research Australia: https://alzheimersresearch.org.au/ Our Special Guests: Dr Liam Mulcahy is a physician trainee with an interest in neurology and author of Beyond the White Coat Dr Daniel Clarke is a consultant neurologist and director of clinical trials at Alzheimer’s Research Australia Dr Gemma Daley is a consultant chemical pathologist at Sullivan Nicolaides Pathology Listen: This Medical Life podcast is available on all podcasting services, Apple Podcasts, YouTube, and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page. See omnystudio.com/listener for privacy information.

Two teenage patients, thirty years apart, changed how bone sarcomas are treated. In 1890, seventeen-year-old Bessie Dashiell saw New York surgeon William Coley with a painful hand. Despite an amputation, she died of metastatic cancer ten weeks later. Coley’s search for a better answer led him to Coley’s toxin, a bacterial treatment now recognised as an early form of immunotherapy. In 1921, pathologist James Ewing treated a fourteen-year-old girl with a wrist tumour he believed was osteosarcoma. Coley’s toxin failed. Radiotherapy, tried next, worked, even though osteosarcoma is classically radiotherapy-resistant. The tumour turned out to be a different disease entirely, now known as Ewing sarcoma, accounting for around 15 percent of bone sarcomas. Dr Travis Brown traces both stories in detail, then turns to two guests for the clinical picture in 2026. Dr Liz Connolly, medical oncologist at Peter MacCallum Cancer Centre and oncology research fellow at ProCan Children’s Medical Research Institute, covers staging (localised versus advanced), chemotherapy regimens for osteosarcoma and Ewing sarcoma, targeted therapies, and why immunotherapy has so far shown limited benefit in these cancers. She also discusses five-year survival, which sits around 70 percent for localised osteosarcoma or Ewing sarcoma, and why chondrosarcoma remains difficult to treat with drugs. Professor Angela Hong, clinical professor at the University of Sydney and radiation oncologist at Royal Prince Alfred Hospital, explains why Ewing sarcoma responds so well to radiotherapy while osteosarcoma and chondrosarcoma do not, how multidisciplinary teams decide between surgery and radiotherapy, current dosing and an active Australian phase III trial, and why early referral to a sarcoma centre matters regardless of where a patient lives. What to listen for: the diagnostic overlap between early bone sarcoma symptoms and everyday musculoskeletal complaints, and what that means for when to consider imaging and referral. This is the story of Bone Sarcoma Part 2. Find Part 1 here. Useful links: Australia and New Zealand Sarcoma Association: https://sarcoma.org.au/ Find a sarcoma specialist: https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist Sarcoma guidelines: https://sarcoma.org.au/pages/sarcoma-guidelines Seeking a second opinion: https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion Useful patient information: https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information Our Special Guests: Dr Liz Connolly is a medical oncologist who specialises in treating and researching sarcomas Professor Angela Hong is a radiation oncologist and clinical professor at the University of Sydney Listen: This Medical Life podcast is available on all podcasting services, Apple Podcasts, YouTube, and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page. See omnystudio.com/listener for privacy information.

Bone sarcomas are rare, accounting for 0.2% of all cancer diagnoses, with around 200 cases diagnosed in Australia each year. The three main types differ by age and site: osteosarcoma (around 30 to 35% of cases, often in the arms, legs and pelvis, with peaks in adolescence and again in the seventies and eighties), chondrosarcoma (around 30% of cases, typically in adults over 40), and Ewing sarcoma (around 15% of cases, most common in children). Professor Fiona Maclean, an anatomical pathologist, describes bone sarcoma diagnosis as a pattern-recognition challenge made harder by rarity, noting that tumour type and stage are the two most useful pieces of information for a GP reading a pathology report. A/Professor Richard Boyle, an orthopaedic oncological surgeon, outlines the red flags, including unexplained deep bone pain and night pain, and the diagnostic pathway from X-ray through biopsy to multidisciplinary review. This is the story of Bone Sarcoma Part 1. Useful links: Australia and New Zealand Sarcoma Association: https://sarcoma.org.au/ Find a sarcoma specialist: https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist Sarcoma guidelines: https://sarcoma.org.au/pages/sarcoma-guidelines Seeking a second opinion: https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion Useful patient information: https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information Our Special Guests: A/Professor Richard Boyle who is a Sydney-based orthopaedic oncological surgeon and head of the NSW Sarcoma unit. Professor Fiona Maclean who is an anatomical pathologist and professor from Macquarie University. Listen: This Medical Life podcast is available on all podcasting services and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page. See omnystudio.com/listener for privacy information.

The treatment of soft tissue sarcomas is a highly specialised area. The first effective chemotherapy agent against sarcomas was only identified in the 1960s and benefits of adjuvant radiotherapy treatment began in the 1970s. We continue to learn as new agents become available and tailor treatments to each patient. This is the story of Soft Tissue Sarcoma (Part 2). Here is the link to Part 1. Useful links: Australia and New Zealand Sarcoma Association: https://sarcoma.org.au/ Find a sarcoma specialist: https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist Sarcoma guidelines: https://sarcoma.org.au/pages/sarcoma-guidelines Seeking a second opinion: https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion Useful patient information: https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information Article from the RCPA about reviewing soft tissue tumours and obtaining second opinions: https://pubmed.ncbi.nlm.nih.gov/41390329/ Our Special Guests: Professor Peter Grimison who is a medical oncologist at Chris O’Brien Lifehouse and clinical professor at University of Sydney Associate Professor Stephen Thompson is a radiation oncologist at Prince of Wales hospital and conjoint associate professor at the University of New South Wales The treatment of soft tissue sarcomas is a highly specialised area. The first effective chemotherapy agent against sarcomas was only identified in the 1960s and benefits of adjuvant radiotherapy treatment began in the 1970s. We continue to learn as new agents become available and tailor treatments to each patient. This is the story of Soft Tissue Sarcoma (Part 2). Here is the link to Part 1. Useful links: Australia and New Zealand Sarcoma Association: https://sarcoma.org.au/ Find a sarcoma specialist: https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist Sarcoma guidelines: https://sarcoma.org.au/pages/sarcoma-guidelines Seeking a second opinion: https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion Useful patient information: https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information Article from the RCPA about reviewing soft tissue tumours and obtaining second opinions: https://pubmed.ncbi.nlm.nih.gov/41390329/ Our Special Guests: Professor Peter Grimison who is a medical oncologist at Chris O’Brien Lifehouse and clinical professor at University of Sydney Associate Professor Stephen Thompson is a radiation oncologist at Prince of Wales hospital and conjoint associate professor at the University of New South Wales Listen: This Medical Life podcast is available on all podcasting services and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page. See omnystudio.com/listener for privacy information.

Soft tissue sarcomas are tumours that arise from connective tissue, fat, muscle, and blood vessels. They are distinct from epithelial malignancies (carcinomas) in both morphology and behaviour. Unfortunately, due to their rare occurrence, these tumours can be mistaken clinically and pathologically which affects patients management and prognosis. As part of sarcoma awareness month, we are doing a series on soft tissue sarcomas as well as bone sarcoma in conjunction with the Australian & New Zealand Sarcoma Association to raise awareness and help provide education about these diagnoses. This is the story of soft tissue sarcoma (part 1). Useful links: Australia and New Zealand Sarcoma Association: https://sarcoma.org.au/ Find a sarcoma specialist: https://sarcoma.org.au/pages/about-sarcoma/find-a-sarcoma-specialist Sarcoma guidelines: https://sarcoma.org.au/pages/sarcoma-guidelines Seeking a second opinion: https://sarcoma.org.au/pages/about-sarcoma/seeking-second-opinion Useful patient information: https://sarcoma.org.au/pages/about-sarcoma/patient-and-carer-sarcoma-information Article from the RCPA about reviewing soft tissue tumours and obtaining second opinions: https://pubmed.ncbi.nlm.nih.gov/41390329/ Our Special Guests: Associate Professor Richard Boyle who is an orthopaedic oncologist and surgeon who specialises in the bone and soft tissue sarcoma. Professor Fiona Maclean is an anatomical pathologist who specialises in soft tissue pathology and clinical professor at Macquarie University. Listen: This Medical Life podcast is available on all podcasting services and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page. See omnystudio.com/listener for privacy information.

Ethics, codes of conduct, and challenging decisions are universal constants in medicine. Difficult situations and trying to do the right thing are not always obvious particularly when these decisions involve lots of emotions, family members, and have life and death implications. Ethics, and ethics committees, can help to provide a clear and consensus path for clinicians, patients, and family members. We discuss the role ethics and ethics committees have in modern medicine with our special guest. This is the story of clinical ethics. Useful links: Free critical thinking course through UQ school of philosophy Clinical Ethics Society of Australasia – Great organisation focusing on clinical ethics, with affordable membership and lots of access to resources. They run an excellent ‘ethics intensive’ and yearly symposium as well as other masterclasses throughout the year. Australasian Association of Bioethics and Health Law – Major organisation for ethics and health law. Excellent conference each year. Links to Dr Melanie Jansen’s poetry Instragram: @drmelaniejansen_poetry Dr Melanie Jansen’s debut poetry collection, All That Could Be Lost, is available online from 5 Islands Press and at independent bookstores. Our Special Guest: Dr Melanie Jansen who is a clinical ethicist and paediatric intensive care consultant Listen: This Medical Life podcast is available on all podcasting services and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page. See omnystudio.com/listener for privacy information.

Lipoprotein (a) (Lp(a)) was discovered in 1963 by a Norwegian geneticist by the name of Kåre Berg who studied particles that carried cholesterol in the blood. He found some patients had an additional protein on the low-density lipoprotein. Studies found that patients with elevated Lp(a) had increased risks of cardiovascular disease. However, the levels were not affected by diet, environmental factors, or medications. The result is that this test was largely ignored for the last few decades. Recent dyslipidaemia guidelines released by the United States and Europe have returned a focus back on to Lp(a). They recommend that patients should have Lp(a) tested once throughout their life to assess their cardiovascular disease risk. The result can help identify which patients are at a higher risk of cardiovascular morbidity and mortality and who will benefit from lifestyle modification and early intervention. This resource is referenced during the discussion: https://www.lpaclinicalguidance.com/ This is the story of lipoprotein (a). Our Special Guests: Dr Michael Page is a chemical pathologist at Clinipath in Perth, senior lecturer at the UWA Medical School, and immediate past President of the AMA (WA). Listen: This Medical Life podcast is available on all podcasting services and Spotify. Members of the RACGP are able to log the hours as CPD (Education) that they listen to the episodes under self record via Quick log. We invite you to help support us on our donation page. See omnystudio.com/listener for privacy information.

Skin has always told stories. For thousands of years, those whose skin behaved differently — scaling, thickening, inflaming — were feared, isolated, and misunderstood. Psoriasis was long lumped together with leprosy, its sufferers cast out rather than cared for. It would take centuries before medicine began to separate these conditions, and longer still before we understood what was really happening beneath the surface. Psoriasis is not an infection, not a curse, not a failure of hygiene. It is the immune system turning on itself, a complex, chronic inflammatory disease that affects not just skin but joints, confidence, and quality of life. It touches roughly 2-3% of the population, and for many it is a lifelong companion. Today we have a clinical dermatologist and a dermatopathologist to help us understand what psoriasis looks like to the clinician, what it reveals under the microscope, and how our understanding of its immunological roots has transformed the way we treat it. This is the story of psoriasis. Our Special Guests: Associate Professor Laura Scardamaglia, a Consultant Dermatologist, a Fellow of the Australasian College of Dermatology, and Clinical Associate Professor at the University of Melbourne. Dr Grace Liu is an Anatomical Pathologist with Histopath in Sydney, Australia. Listen: This Medical Life podcast is available on all podcasting services and Spotify. Help support us on our donation page. See omnystudio.com/listener for privacy information.

The Artful Dodger is a television series on Disney+ that is a historical medical drama set in 1850s Australia with Jack Dawkins, the Artful Dodger from the world of Oliver Twist. Jack is a former pick pocket now surgeon who is reacquainted with old partner in crime, Fagin, who is keen for Jack to resume old habits. The Artful Dodger takes pride in being one of the most historically accurate depictions of nineteenth century medicine and surgery. The hospital, surgical tools, and treatments are accurate portrayals of what we knew back then. We organised a discussion with its creator to take a deep dive into this entertaining show that both myself and Steve thoroughly enjoyed. This is the story of The Artful Dodger Our Special Guest: James McNamara who is the creator, showrunner, head writer, and executive producer of The Artful Dodger available on Disney+. Listen: This Medical Life podcast is available on all podcasting services and Spotify. Help support us on our donation page. See omnystudio.com/listener for privacy information.

The complex symptomatology of hormonal diseases only started to be recognised in the 19th century as we learned about anatomy and physiology. When Doctor Robert Graves began piecing the hyperthyroid puzzle together when he saw patients with similar symptoms such as anxiousness, nervousness, aggitation, bulging eyes, and rapid/irregular heart rate. He realised this was a previously unknown condition to the medical field. It would not be until the mid-20th century before we had a full understanding of the thyroid and thyroid diseases. Today, we have tests to diagnose and medications to manage. Graves’ disease accounts for 70-80% of all cases of hyperthyroidism. This is the story of Graves’ Disease. Our Guests: Dr Liam Mulcahy who is studying physicians training with a strong interest in neurology. He was written a book called Beyond the White Coat: The Faces Behind Medical Eponyms. Professor Duncan Topliss who is a senior endocrinologist at Alfred Hospital in Melbourne and Professor of Medicine in the Department of Medicine, Monash University. Listen: This Medical Life podcast is available on all podcasting services and Spotify. Help support us on our donation page. See omnystudio.com/listener for privacy information.

It has been well established in studies and articles that cholesterol lowering medications have significant heart morbidity and mortality benefits. However, high dosage trials did not show additional survival benefits but had increasing side-effects for patients. Therefore, the maximum dose for statins is not necessarily the best dose for patients. This is the story of statin dosing. Guest: Professor Simon Dimmitt is a Consultant Physician working in General and Cardiovascular Medicine. He is Clinical Professor of Medicine at the University of Western Australia and Adjunct Professor, School of Medicine & Public Health at the University of Newcastle. His website contains Dose Tables and reviews for a modest subscription: Correct Dosing. Listen: This Medical Life podcast is available on all podcasting services and Spotify. Help support us on our donation page. See omnystudio.com/listener for privacy information.

Crucifixion was a form of punishment, humiliation, and execution. Adopted by the Ancient Romans, crucifixion was used on the State’s worst criminals on lower classes and slaves. As common as it was though, we know very little about how people died on the cross. In this episode, we take a closer look at crucifixion through a medical lens. This image is not historically accurate. It was crafted within the guidelines of Gemini as a stereotypical rendering of crucifixion but our episode gets into the, sadly more brutal, truth. This is the story of crucifixion. Listen: This Medical Life podcast is available on all podcasting services and Spotify. Help support us on our donation page. See omnystudio.com/listener for privacy information.